STOCK TITAN
  1. Home
  2. News
  3. CLX
  4. Clorox Reports Q2 Fiscal Year 2025 Results, Updates Outlook

Clorox Reports Q2 Fiscal Year 2025 Results, Updates Outlook

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
earnings
Rhea-AI Summary

Clorox (NYSE: CLX) reported Q2 FY2025 results with net sales decreasing 15% to $1.69 billion, while organic sales declined 9%. The decrease was primarily due to lapping the retail inventory restoration following the August 2023 cyberattack and recent divestitures. Gross margin improved 30 basis points to 43.8%, driven by cost savings and divestiture benefits.

Diluted EPS increased 105% to $1.54, while adjusted EPS decreased 28% to $1.55. The company grew market share in seven of eight categories and achieved its ninth consecutive quarter of gross margin expansion. Notably, Clorox and P&G announced plans to end their Glad® joint venture by January 31, 2026, with Clorox intending to acquire P&G's 20% interest.

For FY2025, Clorox updated its outlook, expecting net sales between -1% to +2%, and organic sales growth of 4% to 7%. The company raised its adjusted EPS guidance to $6.95-$7.35, representing a 13-19% year-over-year increase.

Clorox (NYSE: CLX) ha riportato risultati per il secondo trimestre dell'anno fiscale 2025 con un calo delle vendite nette del 15%, scendendo a 1,69 miliardi di dollari, mentre le vendite organiche sono diminuite del 9%. La diminuzione è stata principalmente causata dal confronto con il ripristino dell'inventario al dettaglio dopo l'attacco informatico di agosto 2023 e dalle recenti dismissioni. Il margine lordo è migliorato di 30 punti base, raggiungendo il 43,8%, grazie a risparmi sui costi e ai benefici derivanti dalle dismissioni.

L'utile per azione diluito è aumentato del 105%, arrivando a 1,54 dollari, mentre l'utile per azione rettificato è diminuito del 28%, fissandosi a 1,55 dollari. L'azienda ha aumentato la quota di mercato in sette delle otto categorie e ha raggiunto il suo nono trimestre consecutivo di espansione del margine lordo. È importante notare che Clorox e P&G hanno annunciato piani per terminare la loro joint venture Glad® entro il 31 gennaio 2026, con Clorox che intende acquisire il 20% di partecipazione di P&G.

Per l'anno fiscale 2025, Clorox ha aggiornato le sue previsioni, aspettandosi vendite nette tra -1% e +2%, e una crescita delle vendite organiche del 4% al 7%. L'azienda ha rivisto al rialzo le sue previsioni sull'utile per azione rettificato a 6,95-7,35 dollari, rappresentando un aumento del 13-19% rispetto all'anno precedente.

Clorox (NYSE: CLX) reportó resultados del segundo trimestre del año fiscal 2025 con ventas netas en disminución del 15%, alcanzando 1.69 mil millones de dólares, mientras que las ventas orgánicas cayeron un 9%. La disminución se debió principalmente a la comparación con la restauración del inventario minorista tras el ciberataque de agosto de 2023 y a recientes desinversiones. El margen bruto mejoró en 30 puntos básicos hasta el 43.8%, impulsado por ahorros de costos y beneficios de las desinversiones.

El EPS diluido aumentó un 105%, llegando a 1.54 dólares, mientras que el EPS ajustado disminuyó un 28%, situándose en 1.55 dólares. La compañía incrementó su participación de mercado en siete de ocho categorías y logró su noveno trimestre consecutivo de expansión del margen bruto. Notablemente, Clorox y P&G anunciaron planes para finalizar su colaboración en la marca Glad® para el 31 de enero de 2026, con Clorox en intención de adquirir el 20% de participación de P&G.

Para el año fiscal 2025, Clorox actualizó su pronóstico, esperando un crecimiento de ventas netas entre -1% y +2%, y un crecimiento en ventas orgánicas del 4% al 7%. La empresa elevó su guía de EPS ajustado a 6.95-7.35 dólares, lo que representa un aumento del 13-19% en comparación con el año anterior.

클로락스 (NYSE: CLX)는 2025 회계연도 2분기 결과를 발표했으며, 순 매출이 15% 감소하여 16억 9천만 달러에 이를 것으로 보이고, 유기적 매출도 9% 감소했습니다. 이러한 감소는 2023년 8월 사이버 공격 이후 소매 재고 복구와 최근의 자산 매각과 관련이 있습니다. 총 마진은 비용 절감 및 자산 매각 혜택으로 30 베이시스 포인트 개선되어 43.8%에 도달했습니다.

희석 EPS는 105% 증가하여 1.54달러에 이르렀고, 조정된 EPS는 28% 감소하여 1.55달러에 도달했습니다. 회사는 8개 카테고리 중 7개에서 시장 점유율을 확대했으며, 총 마진이 9분기 연속 확장되었습니다. 특히, 클로락스와 P&G는 2026년 1월 31일까지 Glad® 합작 투자 종료 계획을 발표했으며, 클로락스는 P&G의 20% 지분을 인수할 계획입니다.

2025 회계연도에 대해 클로락스는 전망을 업데이트하여, 순 매출이 -1%에서 +2% 사이일 것으로 예상하고, 유기적 매출 성장률은 4%에서 7% 사이일 것으로 보입니다. 회사는 조정된 EPS 가이드를 6.95-7.35달러로 상향 조정했으며, 이는 전년 대비 13-19% 증가를 의미합니다.

Clorox (NYSE: CLX) a annoncé des résultats pour le deuxième trimestre de l'exercice 2025, avec des ventes nettes en baisse de 15% à 1,69 milliard de dollars, tandis que les ventes organiques ont diminué de 9%. Cette diminution est principalement due à la comparaison avec la restauration des stocks de détail suite à l'attaque cybernétique d'août 2023 et à des cessions récentes. La marge brute s'est améliorée de 30 points de base pour atteindre 43,8%, soutenue par des économies de coûts et des avantages liés aux cessions.

Le BPA dilué a augmenté de 105% pour atteindre 1,54 dollar, tandis que le BPA ajusté a diminué de 28% pour se chiffrer à 1,55 dollar. L'entreprise a gagné des parts de marché dans sept des huit catégories et a réalisé son neuvième trimestre consécutif d'expansion de la marge brute. Notamment, Clorox et P&G ont annoncé leur intention de mettre fin à leur coentreprise Glad® d'ici le 31 janvier 2026, Clorox ayant l'intention d'acquérir la participation de 20% de P&G.

Pour l'exercice 2025, Clorox a mis à jour ses prévisions, s'attendant à des ventes nettes comprises entre -1% et +2%, et une croissance des ventes organiques de 4% à 7%. L'entreprise a relevé ses prévisions de BPA ajusté à 6,95 à 7,35 dollars, représentant une augmentation de 13 à 19% par rapport à l'année précédente.

Clorox (NYSE: CLX) hat die Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 veröffentlicht, wobei die Nettoumsätze um 15% auf 1,69 Milliarden Dollar zurückgingen und die organischen Umsätze um 9% sanken. Der Rückgang war hauptsächlich auf die Nachverfolgung der Wiederherstellung der Einzelhandelsbestände nach dem Cyberangriff im August 2023 sowie auf jüngste Veräußern zurückzuführen. Die Bruttomarge verbesserte sich um 30 Basispunkte auf 43,8%, was durch Kosteneinsparungen und Vorteile aus Veräußerungen gestützt wurde.

Der verwässerte Gewinn pro Aktie stieg um 105% auf 1,54 Dollar, während der bereinigte Gewinn pro Aktie um 28% auf 1,55 Dollar sank. Das Unternehmen konnte in sieben von acht Kategorien Marktanteile gewinnen und erreichte das neunte aufeinanderfolgende Quartal mit einer Bruttomargenexpansion. Bemerkenswert ist, dass Clorox und P&G Pläne bekannt gaben, ihr gemeinsames Unternehmen Glad® bis zum 31. Januar 2026 zu beenden, wobei Clorox beabsichtigt, die 20%ige Beteiligung von P&G zu übernehmen.

Für das Geschäftsjahr 2025 hat Clorox seine Prognose aktualisiert und erwartet einen Nettoumsatz zwischen -1% und +2% sowie ein organisches Umsatzwachstum zwischen 4% und 7%. Das Unternehmen hat seine bereinigte Gewinnprognose auf 6,95 bis 7,35 Dollar angehoben, was einem Anstieg von 13-19% im Jahresvergleich entspricht.

Positive
  • Gross margin improved 30 basis points to 43.8%
  • Diluted EPS increased 105% to $1.54
  • Market share growth in 7 of 8 categories
  • Operating cash flow increased 132% to $401 million year-to-date
  • Raised FY2025 adjusted EPS guidance to $6.95-$7.35
  • Ninth consecutive quarter of gross margin expansion
Negative
  • Net sales decreased 15% to $1.69 billion
  • Organic sales declined 9%
  • Adjusted EPS decreased 28% to $1.55
  • Health and Wellness segment sales decreased 13%
  • Household segment adjusted EBIT decreased 48%
  • Lifestyle segment sales decreased 16%

Insights

Clorox's Q2 FY2025 results reveal a complex narrative of strategic transformation amid post-cyberattack normalization. While the headline 15% revenue decline appears concerning, it's primarily due to lapping effects from the 2023 cyberattack recovery and strategic divestitures. The underlying business fundamentals show resilience, with market share gains in 7 out of 8 categories.

The planned acquisition of P&G's 20% stake in the Glad business represents a strategic pivot. Full control of Glad operations should streamline decision-making and potentially accelerate innovation in the profitable bags and wraps segment. The retention of P&G's core IP licenses on a royalty-free basis is particularly valuable, preserving key technological advantages while eliminating partnership complexities.

Notably, Clorox achieved its ninth consecutive quarter of gross margin expansion, reaching 43.8%. This consistent improvement, supported by cost-saving initiatives, suggests the company's pricing power and operational efficiency programs are delivering results. The updated outlook for 125-150 basis points margin expansion reflects confidence in these initiatives.

The upcoming ERP transition represents both an opportunity and a risk. While it's expected to generate $0.25-$0.45 EPS benefit from incremental shipments in FY2025, this will reverse in early FY2026, creating potential volatility. However, the long-term benefits of enhanced digital capabilities and streamlined operations should outweigh these temporary effects.

Segment performance reveals challenges in the core business units, with Health and Wellness, Household and Lifestyle all experiencing double-digit sales declines. However, the International segment's organic growth of 6% (excluding Argentina) demonstrates success in emerging markets and potential for geographical diversification.

OAKLAND, Calif., Feb. 3, 2025 /PRNewswire/ -- The Clorox Company (NYSE: CLX) today reported results for the second quarter of fiscal year 2025, which ended Dec. 31, 2024. Alongside these results, the company also announced that Clorox and P&G have jointly decided to wind down the Glad® bags and wraps joint venture as of Jan. 31, 2026, and the company intends to acquire P&G's 20% interest in the venture at its termination.  

Second-Quarter Fiscal Year 2025 Summary

Following is a summary of key results for the second quarter, which reflect the lapping of the operational recovery following the August 2023 cyberattack. Results also reflect the prior divestitures of the Better Health Vitamins, Minerals and Supplements (VMS) and Argentina businesses. All comparisons are with the second quarter of fiscal year 2024 unless otherwise stated.

  • Net sales decreased 15% to $1.69 billion compared to a 16% net sales increase in the year-ago quarter. The decrease was primarily driven by lapping the impact of retail inventory restoration following the August 2023 cyberattack and the divestitures of the VMS and Argentina businesses. Organic sales1 decreased 9%.
  • Gross margin increased 30 basis points to 43.8% from 43.5% in the year-ago quarter, primarily driven by cost savings and the benefits from the divestitures of the VMS and Argentina businesses, partially offset by lower cost absorption and higher manufacturing and logistics and commodities costs.
  • Diluted net earnings per share (diluted EPS) increased 105% to $1.54 from 75 cents in the year-ago quarter. The increase includes lapping the pension settlement charge and incremental cyberattack expenses, and the current-period benefit of cyberattack insurance recoveries.
  • Adjusted EPS1 decreased 28% to $1.55 from $2.16 in the year-ago quarter, primarily due to lower net sales, partially offset by cost savings.
  • Year-to-date net cash provided by operations was $401 million compared to $173 million in the year-ago period, representing a 132% increase.

"We achieved better-than-expected results across sales, margin and EPS in the second quarter due to our strong demand creation plans, which also supported our share growth. Our results underscore the resiliency of our portfolio as we continue to invest in our brands to deliver superior value to win with consumers at a time when they need it most," said Chair and CEO Linda Rendle. "We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long term, profitable growth."

This press release includes certain non-GAAP financial measures. See "Non-GAAP Financial Information" at the end of this press release for more details.

Strategic and Operational Highlights

The following are recent strategic and operational highlights:

  • Grew share in seven of its eight categories, supported by strong demand creation plans as the company laps the impact of the cyberattack.
  • Launched platform-expanding innovations including the new Hidden Valley Ranch Easy Squeeze bottle and collaborations with Taco Bell and Burger King, the relaunch of Poett's fragrance platform with essential oils and new scents, a full suite of Brita Plus pitchers and dispensers, and the new Fresh Step Heavy Duty Litter. Seeing strong continued success with previously introduced innovation such as Bahama Bliss scented Glad ForceFlex MaxStrength trash bags.
  • Achieved the ninth consecutive quarter of gross margin expansion, supported by another strong quarter of cost savings. The company is on track to fully rebuild gross margin in fiscal year 2025.
  • Recognized with the Household & Commercial Products Association's 2024 Innovation Award for Technology for using AI in development of Clorox Foaming Toilet Bomb Toilet Bowl Cleaner and received the ISSA Environment & Sustainability Innovation of the Year Award for Clorox EcoClean Disinfecting Wipes.
  • Achieved zero-waste-to-landfill (ZWtL) status at its litter manufacturing plant in Martinsburg, West Virginia, marking continued progress toward its goal to achieve ZWtL in 100% of its global facilities where infrastructure allows by 2030.

Key Segment Results

The following is a summary of key second-quarter results by reportable segment. Second-quarter results reflect the lapping of the retail inventory restoration following the August 2023 cyberattack. All comparisons are with the second quarter of fiscal year 2024 unless otherwise stated.

Health and Wellness (Cleaning; Professional Products)

  • Net sales decreased 13%, driven by 11 points of lower volume and 2 points of unfavorable price mix.
  • Segment adjusted EBIT2 decreased 25%, primarily behind lower net sales.

Household (Bags and Wraps; Cat Litter; Grilling)

  • Net sales decreased 11%, driven by 11 points of lower volume.
  • Segment adjusted EBIT decreased 48%, primarily due to lower net sales and higher manufacturing and logistics costs, partially offset by cost savings.

Lifestyle (Food; Water Filtration; Natural Personal Care)

  • Net sales decreased 16%, driven by 16 points of lower volume.
  • Segment adjusted EBIT decreased 36%, primarily due to lower net sales.

International (Sales Outside the U.S.)

  • Net sales decreased 12%, mainly driven by the impact of the Argentina divestiture. Excluding Argentina and 2 points of foreign exchange rate changes, organic sales1 grew 6%, driven by 6 points of organic volume growth.
  • Segment adjusted EBIT decreased 34%, mainly driven by the Argentina divestiture.

Joint Venture to End, Clorox to Acquire P&G's Interest in Glad Business

Clorox and P&G have jointly decided to wind down the Glad® bags and wraps joint venture. It will end on Jan. 31, 2026, and Clorox intends to acquire P&G's 20% interest in the venture at its termination. Clorox's purchase of P&G's interest in the Glad business will be at a fair market value as established by predetermined contractual valuation procedures as of the expiration date of the joint venture.

"We are excited to assume full control of the Glad business and thank P&G for their productive partnership over the past two decades," said Rendle. "Consistent with our IGNITE strategy, we are confident that we will continue to drive profitable growth with strong innovation and superior value going forward, fully leveraging a streamlined operating model and enhanced digital capabilities that allows for greater agility and faster decision making." 

Following expiration of the joint venture, Clorox expects that the Glad business will retain the exclusive core intellectual property licenses contributed by P&G on a royalty-free basis for certain licensed products. In addition to the purchase of P&G's interest in the Glad joint venture, Clorox intends to continue its licensing agreement for Febreze® and Gain® trademarks from P&G.  

Fiscal Year 2025 Outlook

This fiscal year 2025 outlook does not include any potential impact from tariffs.

The company is updating the following elements of its fiscal year 2025 outlook:

  • The company now expects net sales to be down 1% to up 2%, including 1 to 2 points of benefit from incremental shipments related to the Enterprise Resource Planning (ERP) transition, which is expected to reverse in the front half of the next fiscal year. Organic sales are now expected to be up 4% to up 7%, excluding about 2 points of negative impact from the divestiture of the company's business in Argentina and about 3 points of negative impact from the divestiture of the VMS business. Excluding the incremental shipments related to the ERP transition, the company continues to expect organic sales to be up 3% to 5%.
  • Gross margin is now expected to be up 125 to 150 basis points, primarily due to the benefits of holistic margin management efforts, partially offset by cost inflation and higher trade promotion spending. This compares to the previous expectation of 100 to 150 basis points.
  • The company's effective tax rate is now expected to be about 26%. Excluding the impact of the VMS sale, the company expects its fiscal year adjusted effective tax rate to be about 23%.
  • Fiscal year diluted EPS is now expected to be between $5.52 and $5.92 versus previously $5.17 and $5.42, a year over year increase of 145% to 163%, respectively, reflecting the lapping of several one-time charges recorded in the year-ago period. This includes the profit from incremental shipments related to the ERP transition of 25 cents to 45 cents, which is expected to reverse in the front half of fiscal year 2026.
  • Adjusted EPS is now expected to be between $6.95 and $7.35 compared to the previous estimate of $6.65 and $6.90, a year over year increase of 13% to 19%, respectively. The main change is to reflect a 25 to 45 cent net benefit from the expected incremental shipments related to the company's ERP transition. Aside from this change, adjusted EPS also assumes lower input costs and a lower tax rate as compared to the previous outlook. Adjusted EPS excludes about 70 cents of expense from long-term strategic investments in digital capabilities and productivity enhancements, a 94 cent charge in the first quarter from the loss on sale related to the divestiture of the VMS business, and a 21 cent benefit from cyberattack insurance recoveries in the first half of this fiscal year.

The company is confirming the following elements of its fiscal year 2025 outlook:

  • Selling and administrative expenses continue to be expected to be between 15% to 16% of net sales, which includes about 150 basis points of impact from the company's strategic investments in digital capabilities and productivity enhancements.
  • Advertising and sales promotion spending is still expected to be 11% to 11.5% of net sales, reflecting the company's ongoing commitment to invest behind its brands.

___________________

1

Organic sales growth / (decrease) and adjusted EPS are non-GAAP measures. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

2

Adjusted EBIT is a non-GAAP measure. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

Clorox Earnings Conference Call Schedule 

At approximately 4:15 p.m. ET today, Clorox will post prepared management remarks regarding its second quarter fiscal year 2025 results.

At 5 p.m. ET today, the company will host a live Q&A audio webcast with Chair and CEO Linda Rendle, Chief Financial Officer Kevin Jacobsen and Treasurer and incoming Chief Financial Officer Luc Bellet to discuss the results.

Links to the live (and archived) webcast, press release and prepared remarks can be found at Clorox Quarterly Results.

For More Detailed Financial Information 

Visit the company's Quarterly Results for the following: 

  • Supplemental unaudited volume and sales growth information
  • Supplemental unaudited gross margin drivers information
  • Supplemental unaudited cash flow information and free cash flow reconciliation
  • Supplemental unaudited reconciliation of earnings (losses) before interest and taxes (EBIT) and adjusted EBIT
  • Supplemental unaudited reconciliation of adjusted earnings per share (EPS) and adjusted effective tax rate (ETR)

Note: Percentage and basis-point, or point, changes noted in this press release are calculated based on rounded numbers, except for per-share data and the effective tax rate.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Its trusted brands include Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr® and Pine-Sol® as well as international brands such as Clorinda®, Chux® and Poett®. Headquartered in Oakland, California, since 1913, Clorox was one of the first U.S. companies to integrate ESG into its business reporting. In 2024 the company was ranked No. 1 on Barron's 100 Most Sustainable Companies list for the second consecutive year. Visit thecloroxcompany.com to learn more.

CLX-F

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements regarding the expected or potential impact of the company's operational disruption stemming from a cyberattack, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "will," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations, are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024, as updated from time to time in the company's Securities and Exchange Commission filings. These factors include, but are not limited to: unfavorable general economic and geopolitical conditions beyond our control, including supply chain disruptions, labor shortages, wage pressures, rising inflation, the interest rate environment, fuel and energy costs, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, such as COVID-19, terrorism, and unstable geopolitical conditions, including ongoing conflicts in the Middle East and Ukraine and rising tensions between China and Taiwan, as well as macroeconomic and geopolitical volatility and uncertainty as a result of a number of these and other factors, including actual and potential shifts in U.S. and foreign trade policies, including as a result of escalating trade tensions between the U.S. and its trading partners, especially China; the ability of the company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix; the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences; our recovery from the August 2023 cyberattack, and risks related to the company's use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or company information, business, service or operational disruptions, or that impact the company's financial results or financial reporting, or any resulting unfavorable outcomes, increased costs or legal proceedings; intense competition in the company's markets; volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services; risks related to supply chain issues, product shortages and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers; the ability of the company to implement and generate cost savings and efficiencies, and successfully implement its transformational initiatives or strategies, including achieving anticipated benefits and cost savings from the implementation of the streamlined operating model and digital capabilities and productivity enhancements; the company's ability to maintain its business reputation and the reputation of its brands and products; dependence on key customers and risks related to customer consolidation and ordering patterns; the ability of the company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries; the company's ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market, such as increasing labor costs and sustained labor shortages; lower revenue, increased costs or reputational harm resulting from government actions and compliance with regulations, or any material costs imposed by changes in regulation; changes to our processes and procedures as a result of our digital capabilities and productivity enhancements investment that may result in changes to the company's internal controls over financial reporting; the ability of the company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity; risks related to international operations and international trade, including changing macroeconomic conditions as a result of inflation, volatile commodity prices and increases in raw and packaging materials prices, labor, energy and logistics; global economic or political instability; foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; potential operational or supply chain disruptions from wars and military conflicts, including ongoing conflicts in the Middle East and Ukraine and rising tensions between China and Taiwan; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action; the impact of Environmental, Social, and Governance (ESG) issues, including those related to climate-related transition risks, changing consumer preferences, including the environmental impact of the Company's products and sustainability on our sales, operating costs or reputation; the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls; risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions; the accuracy of the company's estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based; risks related to the acquisition of The Procter & Gamble Company's interest in the Glad business; risks related to our reliance on third-party service providers, including inability to meet cost savings or efficiencies, business or systems disruptions, and other liabilities, including legal or regulatory risk; environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances; the company's ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the company of third-party intellectual property rights; the effect of the company's indebtedness and credit rating on its business operations and financial results and the company's ability to access capital markets and other funding sources, as well as the cost of capital to the company; the company's ability to pay and declare dividends or repurchase its stock in the future; the impacts of potential stockholder activism; and risks related to any litigation associated with the exclusive forum provision in the company's bylaws.

The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this press release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

Non-GAAP Financial Information

  • This press release contains non-GAAP financial information related to organic sales growth / (decrease), adjusted EPS, adjusted effective tax rate ("adjusted ETR") and segment adjusted EBIT for the second quarter of fiscal year 2025, as well as adjusted EPS outlook and adjusted ETR outlook for fiscal year 2025. The reasons management believes these measures are useful to investors are described below. Certain non-GAAP financial measures may be considered in determining incentive compensation.
     
  • Clorox defines organic sales growth / (decrease) as GAAP net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures.
     
  • Organic sales growth/(decrease) outlook for fiscal year 2025 excludes about 2 points of negative impact from the divestiture of the company's business in Argentina and about 3 points of negative impact from the divestiture of the Better Health VMS business. Organic sales growth/(decrease) outlook excluding the incremental shipments related to the ERP transition excludes 1 to 2 points of positive impact from the incremental shipments related to the ERP transition.
     
  • Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating and expects to continue to operate throughout the relevant periods, and the company's estimate of the impact of foreign exchange rate changes, which are difficult to predict and out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
     
  • Adjusted EPS is defined as diluted earnings per share that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
     
  • Adjusted ETR is defined as the effective tax rate that excludes or that has otherwise been adjusted for significant items that are nonrecurring or unusual.
     
  • Adjusted EPS and adjusted ETR are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the pension settlement charge, incremental costs and insurance recoveries, related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time. However, adjusted EPS and adjusted ETR may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
     
  • Adjusted EBIT represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability during the period. The company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Management believes that the presentation of adjusted EBIT excluding these items is useful to investors to assess operating performance on a consistent basis by removing the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations. However, adjusted EBIT may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
     
  • The reconciliation tables below refer to the equivalent GAAP measures adjusted as applicable for the following items:

Divestiture of Better Health Vitamins, Minerals and Supplements Business

As previously disclosed in the first quarter of fiscal year 2025, the company completed the divestiture of its Better Health VMS business in its entirety. The divested business included the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands, relevant trademarks and licenses, and associated manufacturing and distribution facilities in Sunrise, Florida. The transaction is in support of the company's IGNITE strategy and reflects the commitment to continue evolving its portfolio to reduce volatility and accelerate sales growth, as well as structurally improve its margin, in service of driving more consistent and profitable growth over time.

Due to the nature, scope and magnitude of this charge, the company's management believes presenting this charge as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

Cyberattack Costs

As previously disclosed, incremental costs were incurred by the company as the result of the August 2023 cyberattack. These costs related primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs from the resulting disruption to the company's business operations. The company has since received insurance recoveries related to the cyberattack. Costs associated with ongoing cybersecurity monitoring and prevention as well as enhancement to the company's cybersecurity program are not included within this adjustment.

Due to the nature, scope and magnitude of these costs and recoveries, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

Digital Capabilities and Productivity Enhancements Investment 

As announced in August 2021, the company plans to invest in transformative technologies and processes over a five-year period. This investment began in fiscal year 2022, and includes replacement of the company's enterprise resource planning system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. The total incremental transformational investment is expected to be 560 million to 580 million. It is expected that these implementations will generate efficiencies and transform the company's operations in the areas of supply chain, digital commerce, innovation, brand building and more over the long term.

Of the total investment, approximately 70% is expected to represent incremental operating costs primarily recorded within selling and administrative expenses to be adjusted from reported EPS for purposes of disclosing adjusted EPS through fiscal year 2026. About 70% of these operating costs are expected to be related to the implementation of the ERP, with the remaining costs primarily related to the implementation of complementary technologies.

Due to the nature, scope and magnitude of this investment, these costs are considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, will cease at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

The following table provides reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease), the most comparable GAAP measure:


Three months ended Dec. 31, 2024


Percentage change versus the year-ago period


Health and
Wellness


Household


Lifestyle


International


Total
Company (1)

Net sales growth / (decrease) (GAAP)

(13) %


(11) %


(16) %


(12) %


(15) %

Add: Foreign exchange

—


—


—


2


—

Add/(Subtract): Divestitures/acquisitions (2)

—


—


—


16


6

Organic sales growth / (decrease) (non-GAAP)

(13) %


(11) %


(16) %


6 %


(9) %












Six months ended Dec. 31, 2024


Percentage change versus the year-ago period


Health and
Wellness


Household


Lifestyle


International


Total
Company (1)

Net sales growth / (decrease) (GAAP)

8 %


8 %


4 %


(8) %


2 %

Add: Foreign Exchange

—


—


—


2


—

Add/(Subtract): Divestitures/acquisitions (2)

—


—


—


14


5

Organic sales growth / (decrease) (non-GAAP)

8 %


8 %


4 %


8 %


7 %



(1)

Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.

(2)

The divestiture impact is calculated as net sales from the Argentina and Better Health VMS businesses after the respective sale dates in the three and six month year-ago periods.

The following tables provide reconciliations of adjusted diluted earnings per share (non-GAAP) to diluted earnings per share, the most comparable GAAP measure, and adjusted effective tax rate (non-GAAP) to effective tax rate, the most comparable GAAP measure:

Adjusted Diluted Earnings Per Share (EPS) and Adjusted Effective Tax Rate (ETR)





(Dollars in millions except per share data)


























Diluted earnings per share


Effective tax rate





Three months ended


Three months ended





12/31/2024


12/31/2023


% Change


12/31/2024


12/31/2023


As reported (GAAP)


$               1.54


$               0.75


105 %


18.1 %


29.3 %


Pension settlement charge (1)


—


1.04




—


(1.7) %


Cyberattack costs, net of insurance recoveries (2)


(0.15)


0.16




(0.6) %


(0.5) %


Streamlined operating model (3)


—


0.02




—


(0.1) %


Digital capabilities and productivity
enhancements investment (4)


0.16


0.19




0.6 %


(1.0) %


As adjusted (non-GAAP)


$               1.55


$               2.16


(28) %


18.1 %


26.0 %
















Diluted earnings per share


Effective tax rate




Six months ended


Six months ended




12/31/2024


12/31/2023


% Change


12/31/2024


12/31/2023














As reported (GAAP)


$               2.34


$               0.92


154 %


28.2 %


26.7 %


Loss on divestiture (5)


0.94


—




(6.3) %


—


Pension settlement charge (1)


—


1.04




—


(0.6) %


Cyberattack costs, net of insurance recoveries (2)


(0.21)


0.30




(0.1) %


(0.4) %


Streamlined operating model (3)


—


0.02




—


—


Digital capabilities and productivity
enhancements investment (4)


0.34


0.36




0.2 %


(0.7) %


As adjusted (Non-GAAP)


$               3.41


$               2.64


29 %


22.0 %


25.0 %





(1)

During the three and six months ended Dec. 31, 2023, the company incurred approximately $171 ($130 after tax) of costs related to the settlement of the domestic qualified pension plan.


(2)

During the three and six months ended Dec. 31, 2024, the company recognized approximately $25 ($19 after tax) and $35 ($27 after tax), respectively, of insurance recoveries related to the cyberattack. During the three and six months ended Dec. 31, 2023, the company incurred approximately $25 ($19 after tax) and $49 ($37 after tax), respectively, of costs related to the cyberattack. Costs related primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs from the resulting disruption to the company's business operations.            


(3)

During both the three and six months ended Dec. 31, 2023, the company incurred $3 ($2 after tax) of restructuring and related costs, net related to implementation of the streamlined operating model.


(4)

During the three and six months ended Dec. 31, 2024, the company incurred approximately $26 ($20 after tax) and $55 ($42 after tax), respectively, and during the three and six months ended Dec. 31, 2023, the company incurred approximately $32 ($24 after tax) and $59 ($45 after tax), respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. The expenses relate to the following:









Three months ended


Six months ended








12/31/2024


12/31/2023


12/31/2024


12/31/2023






External consulting fees (a)


$                  17


$                  25


$               37


$               46






IT project personnel costs (b)                                  


2


2


4


4






Other (c)


7


5


14


9






Total


$                  26


$                  32


$               55


$               59









(a)

Comprised of third-party consulting fees incurred to assist in the project management and end-to-end systems integration of this transformative investment. The company relies on consultants for certain capabilities required for these programs that the company does not maintain internally. These costs support the implementation of these programs incremental to the company's normal IT costs and will not be incurred following implementation. 



(b)

Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the company considers these costs not reflective of the ongoing costs to operate its business.



(c) 

Comprised of various other expenses associated with the company's new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses.






(5)  

During the six months ended Dec. 31, 2024, the company incurred an after tax charge of $118 related to the divestiture of the Better Health VMS business.














Full year 2025 outlook (estimated range)








Diluted earnings per share


Effective Tax Rate








Low


High


Midpoint





As estimated (GAAP)


$               5.52


$               5.92


26 %





Loss on divestiture


0.94


0.94


(3) %





Cyberattack costs, net of insurance recoveries


(0.21)


(0.21)


—





Digital capabilities and productivity
enhancements investment (6)


0.70


0.70


—





As adjusted (non-GAAP)


$               6.95


$               7.35


23 %







(6)

In fiscal year 2025, the company expects to incur approximately $105-$115 ($80-$87 after tax) of operating expenses related to its digital capabilities and productivity enhancements investment.

The following table provides reconciliation of adjusted EBIT (non-GAAP) to earnings before income taxes, the most comparable GAAP measure:


Reconciliation of earnings before income taxes to
adjusted EBIT


Three months ended


Six months ended


12/31/2024


12/31/2023


12/31/2024


12/31/2023

Earnings before income taxes

$             237


$             136


$             414


$             165

Interest income

(2)


(7)


(5)


(17)

Interest expense

22


26


43


47

Loss on divestiture

—


—


118


—

Pension settlement charge

—


171


—


171

Cyberattack costs, net of insurance recoveries

(25)


25


(35)


49

Streamlined operating model

—


3


—


3

Digital capabilities and productivity enhancements investment 

26


32


55


59

Adjusted EBIT

$             258


$             386


$             590


$             477









 

Condensed Consolidated Statements of Earnings (Unaudited)







Dollars in millions, except per share data











Three months ended


Six months ended




12/31/2024


12/31/2023


12/31/2024


12/31/2023

Net sales


$             1,686


$         1,990


$         3,448


$        3,376

Cost of products sold


948


1,124


1,903


1,978

Gross profit


738


866


1,545


1,398

Selling and administrative expenses


280


322


561


598

Advertising costs


191


186


392


351

Research and development costs


31


32


62


61

Loss on divestiture


—


—


118


—

Pension settlement charge


—


171


—


171

Interest expense


22


26


43


47

Other (income) expense, net


(23)


(7)


(45)


5

Earnings before income taxes


237


136


414


165

Income tax expense


43


40


117


44

Net earnings

194


96


297


121

Less: Net earnings attributable to noncontrolling interests

1


3


5


6

Net earnings attributable to Clorox


$                193


$              93


$            292


$           115










Net earnings per share attributable to Clorox








Basic net earnings per share


$               1.55


$           0.75


$           2.36


$          0.93

Diluted net earnings per share


$               1.54


$           0.75


$           2.34


$          0.92










Weighted average shares outstanding (in thousands)








Basic


123,766


124,176


123,781


124,075

Diluted


124,662


124,620


124,669


124,635

 

Reportable Segment Information









(Unaudited)












Dollars in millions

























Net sales


Net sales


Three months ended


Six months ended


12/31/2024


12/31/2023


% Change(1)


12/31/2024


12/31/2023


% Change(1)

Health and Wellness

$            628


$            720


(13) %


$         1,326


$         1,224


8 %

Household

446


502


(11)


893


827


8

Lifestyle

338


403


(16)


658


632


4

International

274


311


(12)


533


581


(8)

Reportable segment total

1,686


1,936




3,410


3,264



Corporate and Other (2)

—


54


(100)


38


112


(66)

Total

$         1,686


$         1,990


(15) %


3,448


$         3,376


2 %














Segment adjusted EBIT


Segment adjusted EBIT


Three months ended


Six months ended


12/31/2024


12/31/2023


% Change(1)


12/31/2024


12/31/2023


% Change(1)

Health and Wellness 

$            193


$            259


(25) %


$            428


$            363


18 %

Household

48


92


(48) %


108


88


23

Lifestyle

70


109


(36) %


136


128


6

International

21


32


(34) %


56


66


(15)

Reportable segment total

332


492




728


645



Corporate and Other (2)

(74)


(106)


30


(138)


(168)


18

Total

$            258


$            386


(33) %


590


$            477


24 %

Interest income

2


7




5


17



Interest expense

(22)


(26)




(43)


(47)



Loss on divestiture (3)

—


—




(118)


—



Pension settlement (4)

—


(171)




—


(171)



Cyberattack costs, net of insurance recoveries (5)

25


(25)




35


(49)



Streamlined operating model (6)

—


(3)




—


(3)



Digital capabilities and productivity enhancements
investment (7)

(26)


(32)




(55)


(59)



Earnings before income taxes

$            237


$            136


74 %


$            414


$            165


151 %



(1)

Percentages based on rounded numbers.

(2)

Corporate and Other includes the Better Health VMS business.

(3)

Represents the loss on divestiture of the Better Health VMS business of $118 for the six months ended Dec. 31, 2024.

(4)

Represents the pension settlement charge of $171 ($130 after tax) for the three and six months ended Dec. 31, 2023.

(5)

Represents cyberattack insurance recoveries of $25 ($19 after tax) and $35 ($27 after tax), respectively, for the three and six months ended Dec. 31, 2024, and incremental costs of $25 ($19 after tax) and $49 ($37 after tax), respectively, for the three and six months ended Dec. 31, 2023.

(6)

Represents restructuring and related costs, net for implementation of the streamlined operating model of $3 ($2 after tax) for both the three and six months ended Dec. 31, 2023.

(7)

Represents expenses related to the company's digital capabilities and productivity enhancements investment of $26 ($20 after tax) and $55 ($42 after tax) for the three and six months ended Dec. 31, 2024, respectively, and $32 ($24 after tax) and $59 ($45 after tax) for the three and six months ended Dec. 31, 2023, respectively.

 

Condensed Consolidated Balance Sheets






Dollars in millions









12/31/2024


6/30/2024


12/31/2023




(Unaudited)




(Unaudited)

ASSETS






Current assets







Cash and cash equivalents

$               290


$               202


$               355


Receivables, net

603


695


679


Inventories, net

592


637


655


Prepaid expenses and other current assets

147


88


115



Total current assets

1,632


1,622


1,804

Property, plant and equipment, net

1,242


1,315


1,314

Operating lease right-of-use assets

362


360


354

Goodwill

1,219


1,228


1,252

Trademarks, net

501


538


542

Other intangible assets, net

73


143


156

Other assets

548


545


486

Total assets

$            5,577


$            5,751


$            5,908









LIABILITIES AND STOCKHOLDERS' EQUITY






Current liabilities







Notes and loans payable

$               189


$                   4


$               247


Current operating lease liabilities

81


84


92


Accounts payable and accrued liabilities

1,460


1,486


1,649


Income Taxes Payable

—


—


34



Total current liabilities

1,730


1,574


2,022

Long-term debt

2,483


2,481


2,479

Long-term operating lease liabilities

339


334


311

Other liabilities

882


848


852

Deferred income taxes

22


22


26



Total liabilities

5,456


5,259


5,690

Commitments and contingencies






Stockholders' equity






Preferred stock

—


—


—

Common stock

131


131


131

Additional paid-in capital

1,287


1,288


1,245

Retained earnings

68


250


241

Treasury stock

(1,346)


(1,186)


(1,205)

Accumulated other comprehensive net (loss) income

(181)


(155)


(359)



Total Clorox stockholders' (deficit) equity

(41)


328


53

Noncontrolling interests

162


164


165

Total stockholders' equity

121


492


218

Total liabilities and stockholders' equity

$            5,577


$            5,751


$            5,908

 

(PRNewsfoto/The Clorox Company)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clorox-reports-q2-fiscal-year-2025-results-updates-outlook-302366672.html

SOURCE The Clorox Company

FAQ

What caused CLX's 15% sales decline in Q2 FY2025?

The sales decline was primarily due to lapping the retail inventory restoration following the August 2023 cyberattack and the divestitures of the VMS and Argentina businesses.

What is happening with the Glad joint venture between Clorox and P&G?

The joint venture will end on January 31, 2026, with Clorox planning to acquire P&G's 20% interest at fair market value.

What is Clorox's updated sales guidance for FY2025?

Clorox expects net sales to be between -1% to +2%, with organic sales growth of 4% to 7%.

How did CLX's segment performance compare in Q2 FY2025?

All segments showed declines: Health and Wellness -13%, Household -11%, Lifestyle -16%, and International -12%.

What is CLX's projected adjusted EPS range for FY2025?

Clorox raised its adjusted EPS guidance to $6.95-$7.35, representing a 13-19% year-over-year increase.

Stock CLX logo
Clorox Co Del

NYSE:CLX

CLX Rankings

#rank Ranked by Market Cap
#rank Ranked by Dividends

CLX Latest News

Feb 4, 2025
Clorox to Present at 2025 CAGNY Conference
Feb 4, 2025
Hidden Valley Ranch Dips into Designer Fashion with Exclusive MELKE Collab
Jan 28, 2025
Clorox CFO Kevin Jacobsen to Retire; Luc Bellet Named CFO
Jan 14, 2025
CloroxPro's Latest Clean Index Report Reveals Increased Call for Eco-Conscious Solutions
Jan 13, 2025
Clorox Announces Feb. 3 Webcast of Second-Quarter Fiscal Year 2025 Results

CLX Stock Data

18.86B
122.69M
0.19%
80.69%
3.21%
Household & Personal Products
Specialty Cleaning, Polishing and Sanitation Preparations
Link
United States
OAKLAND